Month: August 2021

Opendoor Technologies (NASDAQ:OPEN), the digital platform for residential real estate, turned the corner with its second-quarter results released on Aug. 11. Its adjusted net income and EBITDA (earnings before interest, taxes, depreciation and amortization) both turned positive from negative results last quarter. As a result, using simple measures of its valuation, OPEN stock is worth
0 Comments
In this article FISV Oscar Wong | Moment | Getty Images Company: Fiserv Inc. (FISV) Business: Fiserv provides payment and financial services technology worldwide. The company operates through Acceptance, Fintech, and Payments segments. The Acceptance segment provides point-of-sale merchant acquiring and digital commerce services; mobile payment services; security and fraud protection products; Carat, an omnichannel
0 Comments
How far can a small medical devices company take a celebrity endorsement? The shares of veterinary diagnostics company Zomedica (NYSEAMERICAN:ZOM) surged after an endorsement from Tiger King celebrity Carole Baskin. In response, meme traders bid ZOM stock up sharply. Since the short interest in ZOM stock is high, the news created a dramatic short squeeze. Source:
0 Comments
Clover Health (NASDAQ:CLOV) has been one of the year’s biggest disappointments. The so-called King of SPACs (special purpose acquisition companies), Chamath Palihapitiya, took the health insurer public via one of his Social Capital Hedosophia SPACs. CLOV stock shares almost immediately tumbled after short sellers revealed that it had failed to disclose a government investigation into
0 Comments
Ahead of its second-quarter earnings report, markets sold off shares of Roblox (NYSE:RBLX). However, the gaming platform allayed fears when it posted respectable results. That said, RBLX stock is still relatively expensive compared to other video game stocks like Activision (NASDAQ:ATVI) or Electronic Arts (NASDAQ:EA). Source: Miguel Lagoa / Shutterstock.com Roblox trades at 19 times
0 Comments
Outlier Covid-19 vaccine play Ocugen (NASDAQ:OCGN) stock has been on a negative run in the past three months, losing about 17% of its value. Source: Shutterstock The company failed to gain an emergency use authorization (EUA) from the FDA for Covaxin, the Indian variant of the coronavirus vaccine. Moreover, its partner firm Bharat Biotech is
0 Comments